Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04076579 · ClinicalTrials.gov registry record · Phase 2
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
A Phase 2 study of Sarcoma and Sarcoma Metastatic, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT04076579 is a Phase 2 study of Sarcoma and Sarcoma Metastatic that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 29 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04076579, a Phase 2 study of Sarcoma and Sarcoma Metastatic, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Trabectedin
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2024-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04076579
The ClinicalTrials.gov registry entry for NCT04076579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT04076579 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04076579 about?
NCT04076579 is a clinical study titled "Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma". This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killi...
What is the current status of trial NCT04076579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2020-03-17. Estimated completion is 2024-09-26.
What conditions does trial NCT04076579 study?
This clinical trial studies the following conditions: Sarcoma, Sarcoma Metastatic.
What interventions are being tested in trial NCT04076579?
The interventions under investigation include: Olaparib (DRUG), Trabectedin (DRUG).
Who is sponsoring clinical trial NCT04076579?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04076579 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.